Pharmaceutical industry in China

Global Pharmaceutical Contract Manufacturing Market Trajectory & Analytics to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry in India, Pharmaceutical industry

The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Pharmaceutical Contract Manufacturing estimated at US$100 Billion in the year 2020, is projected to reach a revised size of US$130.2 Billion by 2026, growing at a CAGR of 4.6% over the analysis period.
  • Growth in the global market is set to be driven by positive trends in the broader pharmaceuticals market which is in turn driven by growth in the emerging markets.
  • The U.S. Market is Estimated at $31.6 Billion in 2021, While China is Forecast to Reach $21.1 Billion by 2026
    The Pharmaceutical Contract Manufacturing market in the U.S. is estimated at US$31.6 Billion in the year 2021.

Ada expands its global leadership team to help drive company's rapid growth

Retrieved on: 
Thursday, July 15, 2021
Companies, Industry economics), Life sciences, Aspirin, Bayer, IG Farben, Leverkusen, Pharmaceutical industry in China

Earlier this year, the company announced a $90 million Series B investment led by Leaps by Bayer to further accelerate this growth.

Key Points: 
  • Earlier this year, the company announced a $90 million Series B investment led by Leaps by Bayer to further accelerate this growth.
  • I am thrilled to be joining the team at Ada, and look forward to further shaping the company's already extraordinary success and growth alongside the team."
  • Prior to Ada, Lemari spent over fifteen years working with Bayer Pharmaceuticals, holding various Global and Regional leadership roles across Pharma Commercial Operations.
  • The Ada platform has 11 million users worldwide, and has completed 23 million assessments since its global launch in 2016.

Ada expands its global leadership team to help drive company's rapid growth

Retrieved on: 
Thursday, July 15, 2021
Companies, Industry economics), Life sciences, Aspirin, Bayer, IG Farben, Leverkusen, Pharmaceutical industry in China

Earlier this year, the company announced a $90 million Series B investment led by Leaps by Bayer to further accelerate this growth.

Key Points: 
  • Earlier this year, the company announced a $90 million Series B investment led by Leaps by Bayer to further accelerate this growth.
  • I am thrilled to be joining the team at Ada, and look forward to further shaping the company's already extraordinary success and growth alongside the team."
  • Prior to Ada, Lemari spent over fifteen years working with Bayer Pharmaceuticals, holding various Global and Regional leadership roles across Pharma Commercial Operations.
  • The Ada platform has 11 million users worldwide, and has completed 23 million assessments since its global launch in 2016.

United States Pharmaceutical Drug Delivery Market Prospects, Trends Analysis, Market Size and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacology, Pharmacy, Drug pricing, Pharmaceutical industry in China, Contract manufacturing organization

The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pharmaceutical Drug Delivery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The country research report on the United States pharmaceutical drug delivery market is a customer intelligence and competitive study of the United States market.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of pharmaceutical drug delivery market in the United States.
  • 5) What are the modes of entering the United States pharmaceutical drug delivery market?

Entos Raises $53 Million Series A Round Led by Coatue and Catalio

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China

View the full release here: https://www.businesswire.com/news/home/20210714005480/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210714005480/en/
    The funding round was oversubscribed and represents a unique combination of sophisticated technology and life-sciences investors.
  • Traditional therapeutic discovery is highly complex and entails prolonged timelines, vast training data needs and sub-optimal accuracy.
  • Through the OrbNet platform, Entos has already achieved meaningful customer traction with a growing portfolio of partnerships with industry leaders in pharmaceuticals, chemicals and materials.
  • The funds will also support an aggressive hiring agenda aimed to further strengthen Entos deep bench of science and engineering talent.

MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Retrieved on: 
Wednesday, July 14, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacy, Food and Drug Administration, United States Public Health Service, Good manufacturing practice, Pharmaceutical industry in China

A Canadian GMP DEL complements MediPharm Labs existing Australian TGA GMP certification.

Key Points: 
  • A Canadian GMP DEL complements MediPharm Labs existing Australian TGA GMP certification.
  • The licence can be used for the manufacturing, testing and sale of Active Pharmaceutical Ingredients (API) and pharmaceutical drug products containing cannabis.
  • With the DEL, MediPharm Labs would be eligible for a US Food and Drug Administration (FDA) foreign inspection if a US or other global pharmaceutical customer files a registration application for a pharmaceutical drug product containing MediPharm Labs API.
  • In 2020, 64% of drugs exported from Canadian Drug Establishment Licence holders were exported to the US with FDA approval.

RTW Investments-Backed Ji Xing Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer

Retrieved on: 
Tuesday, July 13, 2021
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Life sciences, Health sciences, Health care, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, XING, Merck, Biopharmaceutical, Pharmaceutical industry in China, RTW Investments, Ji Xing Pharmaceuticals, RTW INVESTMENTS, JI XING PHARMACEUTICALS

Ji Xing Pharmaceuticals (Ji Xing or the Company), a biotechnology company focused on bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that Joseph Romanelli has been named Chief Executive Officer and member of the board of directors, effective immediately.

Key Points: 
  • Ji Xing Pharmaceuticals (Ji Xing or the Company), a biotechnology company focused on bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that Joseph Romanelli has been named Chief Executive Officer and member of the board of directors, effective immediately.
  • Ji Xing is backed by RTW Investments, LP (RTW), a leading healthcare-focused entrepreneurial investment firm with a strong track record of creating companies developing life-changing therapies.
  • Romanelli has more than 25 years of biopharmaceutical and biotechnology experience, nearly all with Merck & Co., Inc. (Merck or MSD).
  • Ji Xing also announced the close of its Series B financing from RTW.

Anti-Counterfeit Packaging Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Technology, Packaging, Manufacturing, Security, Forgery, Pharmaceuticals policy, Counterfeit, Packaging and labeling, Crime, Pharmaceutical industry in China, Articles, Counterfeit consumer goods

The "Anti-Counterfeit Packaging Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-Counterfeit Packaging Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The future of the Anti-counterfeit packaging market looks promising with opportunities in the food & beverage, pharmaceuticals & healthcare, industrial & automotive, consumer durables, and clothing & apparel industries.
  • The major growth drivers for this market are increasing focus of manufacturers on brand protection, and growth of the parent industry.
  • The study includes the Anti-counterfeit packaging market size and forecast for the global Anti-counterfeit packaging market through 2024, segmented by technology, usage feature, end use sector, and by region as follows:

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Health care, Health, Healthcare in India, Pharmaceutical industry in India, Pharmaceutical industry in China, Fiscal year

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2021.
  • No revenue was recognized for the fiscal year ended April 30, 2021, compared to $12.7 million for the prior fiscal year.
  • Research and development expenses were $41.3 million for the fiscal year ended April 30, 2021, compared to $40.2 million for the prior fiscal year.
  • On July 11, 2021, the Board of Directors adopted the KalVista Pharmaceuticals, Inc. 2021 Inducement Equity Incentive Plan (the Plan).

Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams

Retrieved on: 
Monday, July 12, 2021
Life sciences, Health care, Health sciences, BioCryst Pharmaceuticals, Pharmaceutical industry in China, Medication

Together, these management additions strengthen our ability to address the high unmet medical needs for patients facing serious disorders where current treatment options are limited."

Key Points: 
  • Together, these management additions strengthen our ability to address the high unmet medical needs for patients facing serious disorders where current treatment options are limited."
  • He joins Tavanta as CMO from KalVista Pharmaceuticals, Inc. where he served as senior vice president, medical and contributed to the successful transition of KalVista's lead asset into late-stage clinical development.
  • Prior, Dr. Maetzel held senior global medical affairs positions with BioCryst Pharmaceuticals and Cornerstone Biopharma, overseeing manufacturing, regulatory, drug safety, clinical development, and pricing and market access.
  • "It is my pleasure to join Tavanta at such an exciting time in the Company's evolution," said Dr. Maetzel.